No Data
Express News | Chardan Capital Maintains Buy on Cognition Therapeutics, Maintains $11 Price Target
Express News | Cognition Therapeutics Says Masked Analysis Showed Participants Receiving Oral Zervimesine For At Least Least 6 Months Experienced Slower Lesion Growth Than Participants Receiving Placebo
Cognition Therapeutics Successfully Passes Pre-defined Futility Analysis of Phase 2 Study of Oral Zervimesine (CT1812) in Geographic Atrophy
Cognition Therapeutics' VP of Research Co-hosting Precision Medicine Workshop at the Neuroimmunology Drug Development Summit
Cognition Therapeutics Announces Publication of Commercial Manufacturing Process for Lead Alzheimer's Candidate, Zervimesine (CT1812)
B.Riley Financial Maintains Cognition Therapeutics(CGTX.US) With Buy Rating, Raises Target Price to $2
Toup3Sky999 : couldn’t maintain enough volume for the run
74344702 OP : is it gonna go up tomorrow or down?
Toup3Sky999 74344702 OP : hard to say
74344702 OP : thanks
Toup3Sky999 74344702 OP : based on volume thru the day we should be up long as ppl hold